ClinicalTrials.gg
TerminatedNCT06624150Updated Oct 22, 2026

tDCS and Cognitive Training for Restrictive Eating Disorders

A Phase 1 interventional study of Active tDCS sessions, StarStim device and Sham (fake) tDCS sessions in Anorexia Nervosa and Atypical Anorexia Nervosa, sponsored by University of Minnesota. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Minnesota · Phase 1, Interventional, and Basic science

How we know

Why this study was terminated
Slow accrual/low enrollment
Updated Oct 22, 2026Now TerminatedStudy documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Enrollment
137th of 143
1 · median 40
Started
2024
with 12 others
Phase 1
14 of 174
none open now
Registered
154th of 174
by date
Lead sponsor
6 of 174
University of Minnesota

Among the 174 studies in Anorexia Nervosa with a site in United States, this one is the 137th largest by enrollment of the 143 interventional ones that give a count, is one of 13 that started in 2024, is one of 14 in phase 1, and was the 154th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 174 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

This study looks at adults with restrictive eating disorders who are currently receiving outpatient treatment for their eating disorder to examine whether a new brain stimulation technique called non-invasive transcranial direct current stimulation (tDCS) can enhance brain training. Participation involves interviews, assessments, 10 sessions of brain stimulation (active or sham), and computerized brain training over a 3-4 week period, with one post-intervention visit, and one 1-month follow-up visit.

03

Conditions studied

  • Anorexia Nervosa
  • Atypical Anorexia Nervosa

Keywords

  • anorexia nervosa
  • eating disorder
  • brain training
  • brain stimulation
  • fMRI
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • Self-reported enrollment in outpatient-level treatment at local eating disorder treatment centers in the Twin Cities region, and meeting criteria for AN (mild severity, based on greater than or equal to 17.0 kg/m2) or atypical AN diagnosis (based on MINI and EDE assessments).
  • Participant must be capable of giving , based on UCSD Brief Assessment of Capacity to Consent (UBACC) risk assessment.
  • Sufficient spoken English so as to be able to comprehend testing procedures. Normative ranges on a C-RENAL blood panel (panel and ranges specified here: https://labguide.fairview.org/showtest.asp?testid=3321)

Exclusion criteria

Exclusion Criteria:

  • Substance abuse in the participant
  • Neurological condition or other developmental disorder
  • Serious psychiatric disorder known to affect brain functioning and cognitive performance (e.g., schizophrenia, schizoaffective disorder)
  • Medical instability, which will be evident based on required outpatient treatment status. In standard eating disorders treatment, individuals who are not medically stable are referred to higher levels of care (e.g., residential treatment, inpatient). Therefore, if a participant is enrolled in higher level care for their eating disorder diagnosis, this indicates medical instability and they will be excluded from enrollment in this study.
  • tDCS (e.g., history of craniotomy, history of metallic cranial plates, screws, implanted devices).
  • Acute suicidality (suicidalideation with a plan or intent), assessed via MINI suicidality module and Beck Depression Inventory suicide item
  • Acute homicidality (homicidal ideation with a plan or intent), assessed via MINI
  • Moderate, severe or extreme AN diagnostic severity, based on as per criteria (e.g., BMI \<17.0 kg/m2)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Active tDCS

    10 Active tDCS sessions: 10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.

    Device: Active tDCS sessions, StarStim device

  • Sham comparator
    Sham (fake) tDCS

    10 Sham (fake) tDCS sessions: 10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.

    Device: Sham (fake) tDCS sessions

Interventions

  • DeviceActive tDCS sessions, StarStim device

    10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.

  • DeviceSham (fake) tDCS sessions

    10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.

06

What researchers measure

Primary outcomes

  1. the rate of dropout.

    Feasibility and tolerability measure 1. Evaluating for less than 20% dropout over the course of the tDCS for R-EDs study.

    Time frame: 14 days average

  2. Number of participants retained in the tDCS

    Feasibility and tolerability measure 2 . # of participants retained in the tDCS and cognitive training space of the study (80% or more retention will be used as the assessment threshold).

    Time frame: 14 days average

  3. probabilistic reversal learning task

    Change from pre intervention to post intervention scores in probabilistic reversal learning task performance

    Time frame: 14 days average

  4. Dimensional set shifting task

    change from pre to post intervention scores in dimensional set shifting task.

    Time frame: 14 days average

07

Study locations

1 site
  • University of Minnesota
    Minneapolis, Minnesota 55414, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in May 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Oct 2, 2024
StartActual
Aug 2, 2024
Primary completionActual
May 20, 2026
CompletionActual
May 20, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Slow accrual/low enrollment
changed Oct 22, 2026
Documents
Show all 1 update
  1. Oct 22, 2026
    Completed→Terminated
    Why stopped Slow accrual/low enrollment
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06624150
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Aug 2, 2024
Primary completion
May 20, 2026
Completion
May 20, 2026
Last update
Oct 22, 2026

Study contacts

Lisa Anderson
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion